Biotechnology company developing therapies for neurodegenerative diseases using targeted delivery technologies.
Denali Therapeutics Inc. is a pioneering biopharmaceutical company based in South San Francisco, California, focused on the discovery and development of innovative therapies for neurodegenerative diseases across the United States. Established in 2013 and formerly known as SPR Pharma Inc., the company rebranded to Denali Therapeutics Inc. in March 2015 to reflect its specialized focus and commitment to advancing treatment options in neurology.
At the forefront of its research efforts is a robust pipeline featuring promising therapeutic candidates. Denali Therapeutics is actively developing BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently undergoing phase I and phase Ib clinical trials for the treatment of Parkinson's disease. Additionally, the company is advancing DNL310 through phase I/II clinical trials for hunter syndrome and DNL343 in phase 1 trials for amyotrophic lateral sclerosis (ALS).
Further bolstering its pipeline, Denali Therapeutics has completed phase I clinical trials for AR443820/DNL788, targeting ALS, multiple sclerosis (MS), and Alzheimer's disease, and is progressing SAR443122/DNL758 through phase II trials for cutaneous lupus erythematosus. The company collaborates extensively with industry leaders such as Takeda Pharmaceutical Company, Genentech, Sanofi, and academic institutions including Harvard University, leveraging strategic alliances to advance its innovative research initiatives.
Moreover, Denali Therapeutics has forged a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to explore antisense therapies in the realm of neurodegenerative diseases. Committed to scientific excellence and therapeutic innovation, Denali Therapeutics continues to expand its capabilities in addressing the complex challenges posed by neurodegeneration, aiming to make meaningful advancements in patient care and treatment outcomes.